149 related articles for article (PubMed ID: 38693149)
1. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer.
Arroyo Mühr LS; Gini A; Yilmaz E; Hassan SS; Lagheden C; Hultin E; Garcia Serrano A; Ure AE; Andersson H; Merino R; Elfström KM; Baussano I; Dillner J
Nat Commun; 2024 May; 15(1):3679. PubMed ID: 38693149
[TBL] [Abstract][Full Text] [Related]
2. A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.
Wheeler CM; Hunt WC; Cuzick J; Langsfeld E; Pearse A; Montoya GD; Robertson M; Shearman CA; Castle PE;
Int J Cancer; 2013 Jan; 132(1):198-207. PubMed ID: 22532127
[TBL] [Abstract][Full Text] [Related]
3. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
4. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of HPV vaccination in women reaching screening age in Italy.
Carozzi FM; Ocello C; Burroni E; Faust H; Zappa M; Paci E; Iossa A; Bonanni P; Confortini M; Sani C
J Clin Virol; 2016 Nov; 84():74-81. PubMed ID: 27728850
[TBL] [Abstract][Full Text] [Related]
7. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
Du J; Ährlund-Richter A; Näsman A; Dalianis T
Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of HPV 16/18 vaccines on sexually active 18-23 year old women and the impact of HPV vaccination on organized cervical cancer screening.
Sigurdsson K; Sigvaldason H; Gudmundsdottir T; Sigurdsson R; Briem H
Acta Obstet Gynecol Scand; 2009; 88(1):27-35. PubMed ID: 19031282
[TBL] [Abstract][Full Text] [Related]
9. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus seroprevalence in pregnant women following gender-neutral and girls-only vaccination programs in Finland: A cross-sectional cohort analysis following a cluster randomized trial.
Gray P; Kann H; Pimenoff VN; Eriksson T; Luostarinen T; Vänskä S; Surcel HM; Faust H; Dillner J; Lehtinen M
PLoS Med; 2021 Jun; 18(6):e1003588. PubMed ID: 34097688
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
12. [Implementation of HPV vaccination in Germany].
Schreckenberger C; Kaufmann AM; Schneider A
Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
[No Abstract] [Full Text] [Related]
13. Rationale and design of a long term follow-up study of women who did and did not receive HPV 16/18 vaccination in Guanacaste, Costa Rica.
Gonzalez P; Hildesheim A; Herrero R; Katki H; Wacholder S; Porras C; Safaeian M; Jimenez S; Darragh TM; Cortes B; Befano B; Schiffman M; Carvajal L; Palefsky J; Schiller J; Ocampo R; Schussler J; Lowy D; Guillen D; Stoler MH; Quint W; Morales J; Avila C; Rodriguez AC; Kreimer AR;
Vaccine; 2015 Apr; 33(18):2141-51. PubMed ID: 25796338
[TBL] [Abstract][Full Text] [Related]
14. Prevalence and type distribution of human papillomavirus in 5,000 British Columbia women--implications for vaccination.
Moore RA; Ogilvie G; Fornika D; Moravan V; Brisson M; Amirabbasi-Beik M; Kollar A; Burgess T; Hsu R; Towers L; Lo J; Matisic J; Brooks-Wilson A
Cancer Causes Control; 2009 Oct; 20(8):1387-96. PubMed ID: 19475481
[TBL] [Abstract][Full Text] [Related]
15. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
16. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
Peng S; Ferrall L; Gaillard S; Wang C; Chi WY; Huang CH; Roden RBS; Wu TC; Chang YN; Hung CF
mBio; 2021 Jan; 12(1):. PubMed ID: 33468698
[TBL] [Abstract][Full Text] [Related]
17. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
19. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types.
Kavanagh K; Pollock KG; Potts A; Love J; Cuschieri K; Cubie H; Robertson C; Donaghy M
Br J Cancer; 2014 May; 110(11):2804-11. PubMed ID: 24736582
[TBL] [Abstract][Full Text] [Related]
20. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives.
Castellsagué X; Schneider A; Kaufmann AM; Bosch FX
Gynecol Oncol; 2009 Dec; 115(3 Suppl):S15-23. PubMed ID: 19819540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
